Toronto - A group of Canadian physicians who use Artecoll, an injectable currently awaiting FDA approval, is calling for the development of formal clinical guidelines and further research to help avoid adverse patient reactions.
Reviewing Late-Breaking Research From AAD 2024
ReV Up Your Vitiligo Treatment Strategies
Amy Spizuoco, DO, FAOCD: Addressing STDs and Utilizing Dermatopathology With Care in Diverse Patient Populations
The Cutaneous Connection: Splish, Splash, AD Management Starts in the Bath
Melanoma and the Wrong Site
Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy